Table 3.
Sociodemographic and Clinical Characteristics in Cannabis Users versus Cannabis Non-users
| Cannabis users N=295 (38.7%) N (%) |
Cannabis non-users N=467 (61.3%) N (%) |
Statistics | |
|---|---|---|---|
|
| |||
| Age* | 34.2 (8.6) | 39.2 (8.4) | t=8.1, df=760, p<0.0001 |
|
| |||
| Gender | χ2=13.1, df=1, p=0.0003 | ||
| Males | 229 (77.6) | 305 (65.3) | |
| Females | 66 (22.4) | 162 (34.7) | |
|
| |||
| Race | χ2=5.5, df=1, p= 0.02 | ||
| Caucasians | 156 (52.9) | 287 (61.5) | |
| African Americans | 139 (47.1) | 180 (38.5) | |
|
| |||
| Age group | χ2=32.6, df=1, p= <0.0001 | ||
| <35 years | 152 (51.5) | 144 (30.8) | |
| 35–55 years | 143 (48.5) | 323 (69.2) | |
|
| |||
| Mortality | 13 (4.4) | 49 (10.5) | χ2=9.0, df=1, p= 0.003 |
| No Mortality | 282 (95.6) | 418 (89.5) | |
|
| |||
| Smokers | 193 (65.6) | 268 (58.6) | χ2=3.7, df=1, p=0.05 |
| Non-Smokers | 101 (34.4) | 189 (41.4) | |
|
| |||
| No clozapine | 183 (62.0) | 307 (65.7) | χ2=1.1, df=1, p=0.3 |
| Ever on clozapine | 112 (38.0) | 160 (34.3) | |
|
| |||
| Alcohol users | 242 (82.0) | 236 (50.5) | χ2=76.7, df=1, p= <0.0001 |
| Alcohol non-users | 53 (18.0) | 231 (49.5) | |
|
| |||
| Schizophrenia | 148 (50.2) | 254 (54.4) | χ2=15.6, df=2, p=0.0004 |
| Schizoaffective Disorder | 97 (32.9) | 177 (37.9) | |
| Psychosis NOS | 50 (16.9) | 36 (7.7) | |
|
| |||
| Follow up, years* | 7.4 (2.1) | 7.4 (2.3) | t=−0.0, df=760, p=1.0 |
|
| |||
| Global Assessment of Functioning (GAF)* | 37.8 (10.4) | 38.1 (11.0) | t=0.3, df=636, p=0.76 |
| Causes of death | χ2=6.9, df=7, p=0.4 | ||
| Cardiac | 4 (30.8) | 13 (26.5) | |
| Cerebrovascular | 0 (0.0) | 4 (8.2) | |
| Cancer | 0 (0.0) | 4 (8.2) | |
| HIV/AIDS | 1 (7.7) | 2 (4.1) | |
| Non-HIV Infections | 2 (15.4) | 6 (12.2) | |
| Diabetes | 1 (7.7) | 0 (0.0) | |
| Respiratory | 0 (0.0) | 2 (4.1) | |
| Other | 5 (38.5) | 18 (36.7) | |
| Suicide | 2 (40) | 1 (5.6) | |
| End stage diabetic renal disease | 1 (20) | 2 (11.1) | |
| Alcohol, Narcotic, Clozapine intoxication | 2 (40) | 4 (22.2) | |
| Seizure disorder | 3 (16.7) | ||
| Acute Thermal Injury of Airway and Smoke Inhalation | 1 (5.6) | ||
| Bowel obstruction | 1 (5.6) | ||
| Anoxic encephalopathy, encephalopathy | 3 (16.7) | ||
| Hypoxemia | 1 (5.6) | ||
| Pulmonary hemorrhage | 1 (5.6) | ||
| Myeloproliferative disorder | 1 (5.6) | ||
*
mean (SD)